Ideas
Buy oversold Hyundai and LG for Physical AI rebound.
Hyundai Motor and LG Electronics were oversold amid negative sentiment and the market's sole focus on semiconductors, but physical AI will eventually drive both; with stocks well off their highs and extreme bearishness (people cursing), this marks a bottom and a buying opportunity for a rebound.
AI data centers need massive power, buy power equipment.
The most critical infrastructure for AI data centers is power, not the centers themselves, because data centers consume enormous amounts of electricity. Korean power equipment makers will be direct beneficiaries of the AI-driven power investment wave.
HVM is cheap SpaceX supplier with strong growth.
HVM supplies materials for space launches and benefits regardless of launch success or failure because more launches mean more orders; SpaceX's increasing launch cadence and index inclusion-driven rally support HVM, and the stock has corrected to an attractive 28x forward earnings with strong earnings growth (177bn won this year, 284bn in 2027).
Long Samsung and SK Hynix for AI memory.
Memory is becoming the main component in AI, not just a peripheral part; the long-term uptrend for Samsung Electronics and SK Hynix remains intact, and current weakness is a buying opportunity with a two-year horizon, targeting 800,000 KRW for Samsung Electronics. Near-term consolidation is likely, but the structural AI memory story supports sustained medium-term gains.
Semiconductor equipment super cycle is here.
Korean semiconductor equipment and materials stocks are riding a massive capex cycle; a 10-year super cycle has begun. Stocks like Eugene Technology, PSK, Tes, and KCTech (which makes CMP slurry and is at all-time highs) are leading the move and will continue to benefit from AI-driven semiconductor investment.
MLCC ETF launch draws inflows to Samsung Electro-Mechanics.
A newly launched MLCC-related ETF will attract passive inflows into Samsung Electro-Mechanics, which had been held back by recent market volatility; the ETF creation provides a direct supply-demand catalyst.
PharmaResearch rebounds on Chinese medical tourism.
PharmaResearch has been bashed but its revenue has never declined; a recovery in Chinese medical tourism and cosmetics sales is underway, and the stock is still cheap at 15x next year's earnings against a historical multiple of 40x. A re-rating to 20x would justify a target of 400,000-450,000 KRW, leaving material upside.
Alteogen benefits from national growth fund eligibility.
Alteogen decided to remain listed on KOSDAQ, which makes it eligible for the national growth fund that supports biotech companies; it is positioned as the top beneficiary among biotech names from this government-backed flow catalyst.
This 815 Money Talk (815머니톡) video, published June 30, 2026,
features Lee Kwon-hee
discussing 066570.KS, 005380.KS, 062040.KS, 010120.KS, 298040.KS, HVM, 000660.KS, 005930.KS, 084370.KQ, 095610.KQ, 319660.KS, 028080.KS, 009150.KS, 214450.KQ, 196170.KQ.
8 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Kwon-hee
· Tickers:
066570.KS,
005380.KS,
062040.KS,
010120.KS,
298040.KS,
HVM,
000660.KS,
005930.KS,
084370.KQ,
095610.KQ,
319660.KS,
028080.KS,
009150.KS,
214450.KQ,
196170.KQ